|Mr. Randal J. Kirk||Exec. Chairman||100k||N/A||1953|
|Dr. Helen Sabzevari MPH, Ph.D.||Pres & CEO||614.62k||N/A||1963|
|Mr. Rick L. Sterling||Chief Financial Officer||597.47k||N/A||1964|
|Mr. Donald P. Lehr||Chief Legal Officer & Corp. Sec.||706.23k||N/A||1975|
|Dr. Thomas D. Reed||Founder & Chief Science Officer||N/A||N/A||1966|
Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Intrexon Corporation’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 6.